ranibizumab (Lucentis, Genentech)

Insights from anti-VEGF pivotal DME trialsAnalyses of data collected in the RISE/RIDE and VIVID/VISTA clinical trials provide important messages about the efficacy and safety of ranibizumab (Lucentis, Genentech) and aflibercept (Eylea, Regeneron) for treatment of diabetic macular edema (DME).
Research limited on role of combination therapy for CRVO-related MECombination therapy may be a reasonable approach to manage eyes that are not responding to intravitreal monotherapy with an anti-vascular endothelial growth factor (VEGF) agent or corticosteroid, said Lihteh Wu, MD, at the inaugural Retina World Congress.
ARVO 2016 meeting paves path for personalized medicineEmerging trends and hot topics in eye and vision research filled the sessions at this year’s meeting of the Association for Research in Vision and Ophthalmology.
Study: Fluocinolone acetonide 0.2 µg/day reduced DR progressionTreatment with fluocinolone acetonide 0.2 µg/day significantly reduced progression to proliferative diabetic retinopathy (PDR) in patients who were part of the FAME trials1,2 and had visual acuity loss due to diabetic macular edema (DME), according to Charles C. Wykoff, MD, PhD.
DRCRnet Protocol S results provide evidence for retinopathy advanceResults from the Diabetic Retinopathy Clinical Research Network Protocol S provide evidence for the first major advance in the treatment of proliferative diabetic retinopathy (PDR) in more than 40 years, said Jeffrey Gross, MD.
Bevacizumab 6-week AMD regimen falls short of ranibizumab 4-week regimen
Squalamine for AMD ‘robust’ in eyes containing CNV lesionsCombination treatment with squalamine lactate ophthalmic solution 0.2% and ranibizumab PRN resulted in improved visual function in patients with neovascular age-related macular degeneration compared with treatment with ranibizumab alone.
Observations may provide evidence of systemic effect of anti-VEGF therapyIntravitreal aflibercept may be associated with systemic effects based on an observable reaction in the fellow eyes of patients with diabetic macular edema.
Novartis deterred UK physicians from prescribing Avastin, report saysNovartis attempted to block studies in the United Kingdom comparing ranibizumab (Lucentis) and bevacizumab (Avastin) for the treatment of wet age-related macular degeneration (AMD), according to an article published in The BJM, an international peer-reviewed medical journal.
Switching treatments for wet AMD poses numerous complexities
Switching treatments for wet AMD poses numerous complexitiesStudies that focus on switching treatments for exudative age-related macular degeneration may represent more real-life scenarios. However, future prospective studies with predetermined switching criteria and follow-up are needed.